Switch theme
Sign up to access all valuation multiples
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
2014
31
LTM Revenue $0.4M
Last FY EBITDA -$27.5M
$255M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Corvus Pharma has a last 12-month revenue (LTM) of $0.4M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Corvus Pharma achieved revenue of n/a and an EBITDA of -$27.5M.
Corvus Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Corvus Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.4M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$27.5M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$34.5M | XXX | -$27.5M | XXX | XXX | XXX |
| EBIT Margin | -8876% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$38.6M | XXX | -$62.3M | XXX | XXX | XXX |
| Net Margin | -9923% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Corvus Pharma's stock price is $4.
Corvus Pharma has current market cap of $298M, and EV of $255M.
See Corvus Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $255M | $298M | XXX | XXX | XXX | XXX | $-0.70 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Corvus Pharma has market cap of $298M and EV of $255M.
Corvus Pharma's trades at n/a EV/Revenue multiple, and -9.3x EV/EBITDA.
Equity research analysts estimate Corvus Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Corvus Pharma has a P/E ratio of -7.7x.
See valuation multiples for Corvus Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $298M | XXX | $298M | XXX | XXX | XXX |
| EV (current) | $255M | XXX | $255M | XXX | XXX | XXX |
| EV/Revenue | 655.2x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -9.3x | XXX | XXX | XXX |
| EV/EBIT | -7.4x | XXX | -9.2x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -7.7x | XXX | -4.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -10.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCorvus Pharma's last 12 month revenue growth is 99%
Corvus Pharma's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.9M for the same period.
Corvus Pharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Corvus Pharma's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Corvus Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 99% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Corvus Pharma acquired XXX companies to date.
Last acquisition by Corvus Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Corvus Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Corvus Pharma founded? | Corvus Pharma was founded in 2014. |
| Where is Corvus Pharma headquartered? | Corvus Pharma is headquartered in United States of America. |
| How many employees does Corvus Pharma have? | As of today, Corvus Pharma has 31 employees. |
| Who is the CEO of Corvus Pharma? | Corvus Pharma's CEO is Dr. Richard A. Miller,M.D.. |
| Is Corvus Pharma publicy listed? | Yes, Corvus Pharma is a public company listed on NAS. |
| What is the stock symbol of Corvus Pharma? | Corvus Pharma trades under CRVS ticker. |
| When did Corvus Pharma go public? | Corvus Pharma went public in 2016. |
| Who are competitors of Corvus Pharma? | Similar companies to Corvus Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Corvus Pharma? | Corvus Pharma's current market cap is $298M |
| What is the current revenue of Corvus Pharma? | Corvus Pharma's last 12 months revenue is $0.4M. |
| What is the current revenue growth of Corvus Pharma? | Corvus Pharma revenue growth (NTM/LTM) is 99%. |
| What is the current EV/Revenue multiple of Corvus Pharma? | Current revenue multiple of Corvus Pharma is 655.2x. |
| Is Corvus Pharma profitable? | Yes, Corvus Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
